Sort by:
Need a comprehensive medical report on "Acute Myeloid Leukemia (AML)"?
Analyze the latest clinical research and treatment options
Summarize scientific findings from medical journals
Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T
Phase 2
- Conditions
- De Novo Akute Myeloid Leukemia (AML)Secondary Acute Myeloid Leukemia (AML)Refractory Anemia With Excess of Blasts in Transformation
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2005-11-18
- Lead Sponsor
- Hannover Medical School
- Target Recruit Count
- 200
- Registration Number
- NCT00209833
- Locations
- 🇩🇪
Hannover Medical School, Hannover, Germany
Early Allogeneic Blood Stem Cell Transplantation in High-risk Acute Myeloid Leukemia (AML)
Phase 2
Completed
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2015-12-08
- Lead Sponsor
- University Hospital Carl Gustav Carus
- Target Recruit Count
- 32
- Registration Number
- NCT00188136
- Locations
- 🇩🇪
University hospital Carl Gustav Carus, Dresden, Germany
Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)
Terminated
- Conditions
- Leukemia, Lymphocytic, AcuteLeukemia Acute Promyelocytic Leukemia (APL)Leukemia Acute Lymphoid Leukemia (ALL)LeukemiaLeukemia Chronic Lymphocytic Leukemia (CLL)Leukemia Chronic Myelogenous Leukemia (CML)Leukemia Acute Myeloid Leukemia (AML)
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 88
- Registration Number
- NCT00185523
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML)
Phase 2
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndrome
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2006-02-22
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 25
- Registration Number
- NCT00153582
- Locations
- 🇩🇪
Hematology&Oncology Charité CBF, Berlin, Germany
Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies
Phase 2
Completed
- Conditions
- Acute Lymphoblastic Leukemia (ALL)Acute Myeloid Leukemia (AML)Secondary AMLMyelodysplastic Syndrome (MDS)Secondary MDSChronic Myeloid LeukemiaJuvenile Myelomonocytic Leukemia (JMML)Paroxysmal Nocturnal Hemoglobinuria (PNH)Lymphoma, Non-HodgkinHodgkin Disease
- Interventions
- Procedure: Stem Cell TransplantationDevice: Miltenyi Biotec CliniMACSDrug: Systemic chemotherapy and antibodies
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2009-02-13
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT00145613
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Phase 2
Completed
- Conditions
- Acute Myelogenous LeukemiaMyelodysplastic Syndrome
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2011-03-10
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT00136461
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Phase 2
Terminated
- Conditions
- Leukemia, Myeloid, Acute
- First Posted Date
- 2005-08-12
- Last Posted Date
- 2006-11-03
- Lead Sponsor
- SGX Pharmaceuticals, Inc.
- Target Recruit Count
- 211
- Registration Number
- NCT00129948
- Locations
- 🇺🇸
Scripps Clinic, LaJolla, California, United States
🇺🇸USC-Norris Neuro-Oncology Program, Los Angeles, California, United States
🇺🇸UCSD Moores Cancer Center, San Diego, California, United States
Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)
Phase 1
Completed
- Conditions
- Leukemia, Myeloid
- First Posted Date
- 2005-08-11
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Kanisa Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT00129168
Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
Phase 3
Completed
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2004-10-11
- Last Posted Date
- 2016-09-14
- Target Recruit Count
- 457
- Registration Number
- NCT00093990
PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 1
Completed
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 69
- Registration Number
- NCT00093600
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
🇺🇸Dana Faber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States